To analyze the effect of low-dose IL2 therapy plus rapamycin on the number of Treg, Th17, and ratio of Th17/Treg cells, along with evaluation of therapeutic efficacy of this treatment modality in refractory SLE patients. The gene discussed is IL2; the disease is systemic lupus erythematosus.